SPTX insider buying and SEC filings, explained
Seaport Therapeutics, Inc. · CIK 2042347
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$20.0M
Insiders who bought
2
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jun 22, 2026 | Purchase (code P) | Robert J. Hombach (Director) bought 13,000 shares indirectly (by trust) at about $18.14 ($236K), reported as a purchase (code P). New position of 13,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 24, 2026 |
| May 4, 2026 | Purchase (code P) | Keith Crandell (10% owner) bought 1,100,000 shares indirectly (by entity) at $18.00 ($19.8M), reported as a purchase (code P). Holdings by entity up 21% to 6,294,951 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 6 other reporting owners. | SEC filing Filed May 4, 2026 |
14 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 2, 2026, 7:03 AM ET 8-K | Earnings released (Item 2.02) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow SPTX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.